Literature DB >> 15363033

SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.

Yasuo Sugita1, Osamu Tokunaga, Akihiko Nakashima, Minoru Shigemori.   

Abstract

SHP-1 is an important negative regulator involved in signaling through receptors for cytokine/growth factors, and differential patterns of SHP-1 expression in several types of B-cell lymphomas closely resemble the patterns seen in their normal B cell counterparts. In an effort to elucidate the origin of primary central nervous system lymphomas (PCNSL), the present study assessed 32 cases of PCNSL. Tumors were subclassified according to WHO classification and were evaluated by immunohistochemistry for expression of antigens associated with germinal center (GC) (CD10, Bcl-6) and non-GC stages (SHP-1, CD138). Twenty-nine cases showed diffuse large-cell centroblastic morphology, whereas three cases showed diffuse large-cell immunoblastic morphology. The immunophenotypes of PCNSL were as follows: SHP-1+/Bcl-6-/CD10-/CD138- (12 of 32 cases); SHP-1+/Bcl-6+/CD10-/CD138- (15 of 32 cases); SHP-1+/Bcl-6+/CD10+/CD138- (two of 32 cases); SHP-1+/Bcl-6-/CD10+/CD138- (one of 32 cases); and SHP-1-/Bcl-6-/CD10-/CD138- (two of 32 cases). These results indicate that PCNSL might be distinct lymphomas that originate from a late germinal center to an early postgerminal center.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363033     DOI: 10.1111/j.1440-1827.2004.01677.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.

Authors:  Moo-Kon Song; Joo-Seop Chung; Young-Don Joo; Sang-Min Lee; Sung-Yong Oh; Dong-Hoon Shin; Eun-Young Yun; Seung-Geun Kim; Young-Mi Seol; Ho-Jin Shin; Young-Jin Choi; Goon-Jae Cho
Journal:  J Neurooncol       Date:  2011-03-06       Impact factor: 4.130

2.  Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma.

Authors:  Hiroyuki Momota; Yoshitaka Narita; Akiko M Maeshima; Yasuji Miyakita; Aya Shinomiya; Takashi Maruyama; Yoshihiro Muragaki; Soichiro Shibui
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

3.  Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival.

Authors:  Yasuo Sugita; Yukari Takase; Daisuke Mori; Osamu Tokunaga; Akihiko Nakashima; Minoru Shigemori
Journal:  J Neurooncol       Date:  2006-11-11       Impact factor: 4.506

4.  Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.

Authors:  Kang Hyun Sung; Eun Hee Lee; Young Zoon Kim
Journal:  J Korean Med Sci       Date:  2011-03-28       Impact factor: 2.153

5.  Analysis of Cellular Heterogeneity in Immune Microenvironment of Primary Central Nervous System Lymphoma by Single-Cell Sequencing.

Authors:  Boyuan Wei; Zhe Liu; Yue Fan; Shuwei Wang; Chao Dong; Wei Rao; Fan Yang; Gang Cheng; Jianning Zhang
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

Review 6.  Update on Novel Therapeutics for Primary CNS Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.